View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 3, 2020updated 12 Jul 2022 11:40am

FDA clears Revive Therapeutics’ Covid-19 trial of Bucillamine

Revive Therapeutics has received approval from the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of Bucillamine in patients with mild to moderate Covid-19.

Revive Therapeutics has received approval from the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of Bucillamine in patients with mild to moderate Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Bucillamine is indicated to treat rheumatoid arthritis in Japan and South Korea.

In Covid-19 patients, the drug is expected to increase glutathione activity and other anti-inflammatory activity in order to mitigate the complications of the disease in the lungs.

The multi-centre, randomised, double-blind, placebo-controlled Phase III trial will assess the safety and efficacy in up to 1,000 patients. Participants will be given 100mg or 200mg three times a day or placebo for up to 14 days.

Primarily, the study will track the frequency of hospitalisation or death in patients treated with Bucillamine compared to those on placebo.

The primary endpoint is the proportion of subjects achieving a composite endpoint of hospitalisation or death from the time of first dose to day 28 after randomisation.

Efficacy will be evaluated based on clinical outcome, disease severity, supplemental oxygen use and progression of Covid‑19.

The safety assessment will include pre-treatment adverse events, treatment-emergent adverse events, laboratory values, vital signs, and peripheral oxygen saturation.

An Independent Data and Safety Monitoring Board (DSMB) will conduct an interim analysis after 210 patients receive treatment and are followed up for 28 days after randomisation.

Revive Therapeutics CEO Michael Frank said: “The FDA approval of the Phase III study to evaluate Bucillamine in the treatment of patients with mild-moderate Covid-19 is a tremendous milestone for Revive and I am very proud of the dedication of our team and partners to bring forward a potential new treatment option for patients with a confirmed diagnosis of Covid-19 globally.

“We thank the FDA for recognising the importance of this Phase III study and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner.”

The company filed a clinical trial application with Health Canada in June to conduct a Phase III trial of Bucillamine to treat patients with mild to moderate Covid-19.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena